Toll Free: 1-888-928-9744

AGY Therapeutics, Inc. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 31 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

AGY Therapeutics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'AGY Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the AGY Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AGY Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of AGY Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AGY Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the AGY Therapeutics, Inc.'s pipeline products

Reasons to buy

- Evaluate AGY Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AGY Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AGY Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AGY Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AGY Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of AGY Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
AGY Therapeutics, Inc. Snapshot 5
AGY Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
AGY Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
AGY Therapeutics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
AGY Therapeutics, Inc. - Pipeline Products Glance 11
AGY Therapeutics, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
AGY Therapeutics, Inc. - Drug Profiles 13
Small Molecules for Stroke 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Small Molecules to Agonize AGY-208 for Ischemic Stroke 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Small Molecules to Inhibit AGY-221 for Ischemic Stroke 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Monoclonal Antibody to Inhibit AGY-401 for Glioblastoma Multiforme 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Monoclonal Antibody to Inhibit AGY-402 for Glioblastoma Multiforme 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Monoclonal Antibody to Inhibit GPCR for Glioblastoma Multiforme 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Small Molecules to Inhibit AGY-111 for Cognition and Schizophrenia 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Small Molecules to Inhibit AGY-207 for Ischemic Stroke 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecules to Inhibit Cysteine Protease for Ischemic Stroke 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecules to Inhibit Protein Kinase for Ischemic Stroke 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecules to Inhibit Tyrosine Phosphatase for Cognition and Schizophrenia 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
AGY Therapeutics, Inc. - Pipeline Analysis 24
AGY Therapeutics, Inc. - Pipeline Products by Target 24
AGY Therapeutics, Inc. - Pipeline Products by Route of Administration 25
AGY Therapeutics, Inc. - Pipeline Products by Molecule Type 26
AGY Therapeutics, Inc. - Pipeline Products by Mechanism of Action 27
AGY Therapeutics, Inc. - Dormant Projects 28
AGY Therapeutics, Inc. - Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31
List of Tables
AGY Therapeutics, Inc., Key Information 5
AGY Therapeutics, Inc., Key Facts 5
AGY Therapeutics, Inc. - Pipeline by Indication, 2014 8
AGY Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9
AGY Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10
AGY Therapeutics, Inc. - Preclinical, 2014 11
AGY Therapeutics, Inc. - Discovery, 2014 12
AGY Therapeutics, Inc. - Pipeline by Target, 2014 24
AGY Therapeutics, Inc. - Pipeline by Route of Administration, 2014 25
AGY Therapeutics, Inc. - Pipeline by Molecule Type, 2014 26
AGY Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 27
AGY Therapeutics, Inc. - Dormant Developmental Projects,2014 28 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify